Home
Home

ridaforolimus

FDA Rejection. EU Withdrawal. Set and Match?

FDA Rejection. EU Withdrawal. Set and Match?
Motley Fool

Merck withdraws Marketing Authorisation Application for ridaforolimus in Europe

Merck withdraws Marketing Authorisation Application for ridaforolimus in Europe
The Fly on the Wall

3 Things to Watch at Ariad Pharmaceuticals

3 Things to Watch at Ariad Pharmaceuticals
Motley Fool

Are Ariad's Options Dwindling?

Are Ariad's Options Dwindling?
Motley Fool

Advisory Panel Pans Drug, Investors Shrug?

Advisory Panel Pans Drug, Investors Shrug?
Motley Fool

An FDA Advisory Panel Doubleheader

An FDA Advisory Panel Doubleheader
Motley Fool

FDA Staff Questions Benefits of Glaxo, Merck Cancer Drugs

FDA Staff Questions Benefits of Glaxo, Merck Cancer Drugs
Bloomberg

22 Hot Drugs Facing FDA Approval in 2012

22 Hot Drugs Facing FDA Approval in 2012
TheStreet.com

Merck and Ariad say FDA will review application for their sarcoma pill ridaforolimus

Merck and Ariad say FDA will review application for their sarcoma pill ridaforolimus
Yahoo/AP

Merck-Ariad Drug Under EU Review

Merck-Ariad Drug Under EU Review
Yahoo/Zacks